Jazz Pharmaceuticals Director Patrick G. Enright Files Form 144 to Sell $857K in Common Stock

Executive Summary

On August 31, 2026, Patrick G. Enright, a Director of Jazz Pharmaceuticals plc ($JAZZ), submitted a Form 144 notice declaring the proposed sale of 3,507 shares of common stock with an aggregate market value of approximately $857,602.00 (~$244.54 per share).

Transaction Details

• Security: Common Stock
• Shares Proposed for Sale: 3,507
• Aggregate Market Value: $857,602.00
• Broker: E*TRADE Financial Corporation
• Acquisition Origin: The shares were recently acquired on August 28, 2026, via restricted stock vesting as equity compensation from the issuer.
• Past 3-Month Activity: No prior sales were reported within the past three months.

Significance Assessment

• Significance Level: Low
• Context: The proposed disposition corresponds entirely to newly vested restricted stock units (3,507 shares vested on 08/28/2026). Routine liquidations post-vesting by directors are common and generally reflect standard portfolio diversification or tax obligation management rather than a directional sentiment signal on company fundamentals.